PT93057A - Processo para a preparacao de analogos da insulina - Google Patents

Processo para a preparacao de analogos da insulina

Info

Publication number: PT93057A
Authority: PT; Portugal
Prior art keywords: absent; lys; threonine; arg; aspartic acid
Prior art date: 1989-02-09

Application number

PT93057A

Other languages

English (en)

Other versions

PT93057B (pt

Inventor

Richard Dennis Dimarchi

Ronald Eugene Chance

Bruce Hill Frank

James Edwin Shields

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-02-09

Filing date

1990-02-05

Publication date

1990-08-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26976211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT93057(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1990-02-05 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

1990-08-31 Publication of PT93057A publication Critical patent/PT93057A/pt

1995-12-29 Publication of PT93057B publication Critical patent/PT93057B/pt

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 5
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 5
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 5
239000004473 Threonine Substances 0.000 abstract 5
235000003704 aspartic acid Nutrition 0.000 abstract 5
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 5
235000009582 asparagine Nutrition 0.000 abstract 4
229960001230 asparagine Drugs 0.000 abstract 4
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 3
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 3
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 3
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 abstract 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 abstract 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 2
229930182821 L-proline Natural products 0.000 abstract 2
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical group NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 2
235000004279 alanine Nutrition 0.000 abstract 2
150000001413 amino acids Chemical class 0.000 abstract 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 2
229960002429 proline Drugs 0.000 abstract 2
239000004474 valine Substances 0.000 abstract 2
OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical group NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 abstract 1
JQFZHHSQMKZLRU-IUCAKERBSA-N Arg-Lys Chemical group NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N JQFZHHSQMKZLRU-IUCAKERBSA-N 0.000 abstract 1
ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 abstract 1
ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 abstract 1
229930028154 D-arginine Natural products 0.000 abstract 1
KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 abstract 1
229930182820 D-proline Natural products 0.000 abstract 1
239000004471 Glycine Substances 0.000 abstract 1
101000976075 Homo sapiens Insulin Proteins 0.000 abstract 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 abstract 1
125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 abstract 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical group NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical group NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 abstract 1
NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical group NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 abstract 1
239000004472 Lysine Substances 0.000 abstract 1
OLYPWXRMOFUVGH-LURJTMIESA-N N(2)-methyl-L-lysine Chemical compound CN[C@H](C(O)=O)CCCCN OLYPWXRMOFUVGH-LURJTMIESA-N 0.000 abstract 1
235000001014 amino acid Nutrition 0.000 abstract 1
229940024606 amino acid Drugs 0.000 abstract 1
108010068380 arginylarginine Chemical group 0.000 abstract 1
108010062796 arginyllysine Chemical group 0.000 abstract 1
235000013922 glutamic acid Nutrition 0.000 abstract 1
239000004220 glutamic acid Substances 0.000 abstract 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract 1
235000004554 glutamine Nutrition 0.000 abstract 1
201000001421 hyperglycemia Diseases 0.000 abstract 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
108010054155 lysyllysine Chemical group 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
PMMYEEVYMWASQN-IUYQGCFVSA-N trans-4-hydroxy-D-proline Chemical compound O[C@@H]1CN[C@@H](C(O)=O)C1 PMMYEEVYMWASQN-IUYQGCFVSA-N 0.000 abstract 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- C07K14/622—Insulins at least 1 amino acid in D-form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Diabetes (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Endocrinology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Gastroenterology & Hepatology (AREA)
Animal Behavior & Ethology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Toxicology (AREA)
Genetics & Genomics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Hematology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Compounds Of Unknown Constitution (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PT93057A 1989-02-09 1990-02-05 Processo para a preparacao de analogos da insulina PT93057B (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US30835289A	1989-02-09	1989-02-09
US38820189A	1989-08-04	1989-08-04

Publications (2)

Publication Number	Publication Date
PT93057A true PT93057A (pt)	1990-08-31
PT93057B PT93057B (pt)	1995-12-29

Family

ID=26976211

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT93057A PT93057B (pt)	1989-02-09	1990-02-05	Processo para a preparacao de analogos da insulina

Country Status (24)

Country	Link
EP (2)	EP0383472B1 (pt)
JP (1)	JPH0822878B2 (pt)
KR (1)	KR0169727B1 (pt)
CN (2)	CN1034080C (pt)
AT (1)	ATE133961T1 (pt)
AU (1)	AU630912B2 (pt)
BG (1)	BG60769B2 (pt)
CA (1)	CA2009579C (pt)
CY (1)	CY1911A (pt)
DE (3)	DE19675034I2 (pt)
DK (2)	DK0678522T3 (pt)
ES (2)	ES2083424T3 (pt)
FI (1)	FI95915C (pt)
GR (1)	GR3019501T3 (pt)
HK (1)	HK60296A (pt)
HU (2)	HU212679B (pt)
IE (1)	IE73251B1 (pt)
IL (1)	IL93282A (pt)
LU (2)	LU88831I2 (pt)
NL (1)	NL960026I2 (pt)
NO (2)	NO179587C (pt)
NZ (1)	NZ232375A (pt)
PT (1)	PT93057B (pt)
RU (1)	RU2109749C1 (pt)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5716927A (en) *	1988-12-23	1998-02-10	Novo Nordisk A/S	Insulin analogs having a modified B-chain
AU641631B2 (en) *	1988-12-23	1993-09-30	Novo Nordisk A/S	Human insulin analogues
US5126249A (en) *	1989-05-09	1992-06-30	Eli Lilly And Company	Enzymatic removal of a protein amino-terminal sequence
DK10191D0 (da) *	1991-01-22	1991-01-22	Novo Nordisk As	Hidtil ukendte peptider
US5304473A (en) *	1991-06-11	1994-04-19	Eli Lilly And Company	A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
CZ186492A3 (en) *	1991-06-21	1993-01-13	Lilly Co Eli	Insulin analog, process of its preparation and a pharmaceutical composition containing thereof
GB9316895D0 (en)	1993-08-13	1993-09-29	Guy S And St Thomas Hospitals	Hepatoselective insulin analogues
US6131567A (en) *	1993-01-29	2000-10-17	Aradigm Corporation	Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
EP1607086A1 (en) *	1993-01-29	2005-12-21	Aradigm Corporation	Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
DK72793D0 (da) *	1993-06-21	1993-06-21	Novo Nordisk As	Nyt produkt
US5474978A (en) *	1994-06-16	1995-12-12	Eli Lilly And Company	Insulin analog formulations
US5461031A (en) *	1994-06-16	1995-10-24	Eli Lilly And Company	Monomeric insulin analog formulations
US5504188A (en)	1994-06-16	1996-04-02	Eli Lilly And Company	Preparation of stable zinc insulin analog crystals
US5559094A (en) *	1994-08-02	1996-09-24	Eli Lilly And Company	AspB1 insulin analogs
US5547929A (en) *	1994-09-12	1996-08-20	Eli Lilly And Company	Insulin analog formulations
US5597893A (en)	1994-10-31	1997-01-28	Eli Lilly And Company	Preparation of stable insulin analog crystals
US5646242A (en) *	1994-11-17	1997-07-08	Eli Lilly And Company	Selective acylation of epsilon-amino groups
US5693609A (en) *	1994-11-17	1997-12-02	Eli Lilly And Company	Acylated insulin analogs
AU5724996A (en) *	1995-05-05	1996-11-21	Eli Lilly And Company	Single chain insulin with high bioactivity
US5700904A (en) *	1995-06-07	1997-12-23	Eli Lilly And Company	Preparation of an acylated protein powder
US5631347A (en) *	1995-06-07	1997-05-20	Eli Lilly And Company	Reducing gelation of a fatty acid-acylated protein
DK0921812T4 (da) *	1996-06-20	2012-04-02	Novo Nordisk As	Insulinpræparater, som indeholder et halogenid
DE59711533D1 (de) *	1996-07-26	2004-05-27	Aventis Pharma Gmbh	Insulinderivate mit erhöhter Zinkbindung
SE520392C2 (sv)	1996-09-27	2003-07-01	Creative Peptides Sweden Ab C	Specifika peptider för behandling av diabetes mellitus
DE19726167B4 (de) *	1997-06-20	2008-01-24	Sanofi-Aventis Deutschland Gmbh	Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
JP2001521004A (ja)	1997-10-24	2001-11-06	イーライ・リリー・アンド・カンパニー	脂肪酸−アシル化インスリン類似体
CO4970787A1 (es)	1997-12-23	2000-11-07	Lilly Co Eli	Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
US20010007853A1 (en) *	1998-01-08	2001-07-12	Dimarchi Richard Dennis	Method for administering monomeric insulin analogs
DE19805822B4 (de) *	1998-02-13	2009-02-05	Solvay Pharmaceuticals Gmbh	11-Acetyl-12,13-dioxabicyclo[8.2.1]tridecenon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
CN1125081C (zh) *	1999-09-08	2003-10-22	中国科学院上海生物化学研究所	重组天然和新型人胰岛素及其制备方法
US7638618B2 (en)	2001-02-20	2009-12-29	Sanofi-Aventis Deutschland Gmbh	Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest
US7202059B2 (en)	2001-02-20	2007-04-10	Sanofi-Aventis Deutschland Gmbh	Fusion proteins capable of being secreted into a fermentation medium
DE10114178A1 (de)	2001-03-23	2002-10-10	Aventis Pharma Gmbh	Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
AU2003218635A1 (en) *	2002-05-07	2003-11-11	Novo Nordisk A/S	Soluble formulations comprising insulin aspart and insulin detemir
DE10227232A1 (de)	2002-06-18	2004-01-15	Aventis Pharma Deutschland Gmbh	Saure Insulinzubereitungen mit verbesserter Stabilität
US7193035B2 (en)	2002-10-29	2007-03-20	Sanofi-Aventis Deutschland Gmbh	Crystals of insulin analogs and processes for their preparation
RU2235776C1 (ru) *	2003-03-17	2004-09-10	Институт биоорганической химии им. академиков М.М.Шемякина и Ю.А.Овчинникова РАН	Рекомбинантная плазмидная днк plp-3,1, кодирующая полипептид проинсулина lyspro человека, и штамм бактерий escherichia coli plp-3-1/tg-1-продуцент рекомбинантного проинсулина lyspro
EP2107069B1 (en)	2003-08-05	2013-01-16	Novo Nordisk A/S	Novel insulin derivatives
ES2472421T3 (es)	2003-08-05	2014-07-01	Novo Nordisk A/S	Nuevos derivados de insulina
US20060287221A1 (en)	2003-11-13	2006-12-21	Novo Nordisk A/S	Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
ES2373660T3 (es) *	2003-11-13	2012-02-07	Novo Nordisk A/S	Composición farmacéutica que comprende un análogo insulinotrópico de glp-1 (7-37), insulina asp(b28) y un tensioactivo.
PT1687019T (pt)	2003-11-20	2018-02-26	Novo Nordisk As	Formulações de péptidos que contêm polietileno glicol que são ótimas para produção e para utilização em dispositivos de injeção
JP5697831B2 (ja)	2003-12-03	2015-04-08	ノヴォノルディスクアー／エス	単鎖インシュリン
CN103223160B (zh)	2004-07-19	2015-02-18	比奥孔有限公司	胰岛素-低聚物共轭物,制剂及其用途
JP5410020B2 (ja)	2005-02-02	2014-02-05	ノヴォノルディスクアー／エス	インスリン誘導体
ES2438145T3 (es)	2005-02-02	2014-01-16	Novo Nordisk A/S	Nuevos derivados de insulina
JPWO2006093222A1 (ja) *	2005-03-02	2008-08-07	味の素株式会社	インスリンの多量体形成阻害剤
CN102660614A (zh)	2005-08-16	2012-09-12	诺沃-诺迪斯克有限公司	制备成熟胰岛素多肽的方法
MY146082A (en)	2005-09-14	2012-06-29	Sanofi Aventis Deutschland	Cleavage of precursors of insulins by a variant of trypsin
US20090074882A1 (en)	2005-12-28	2009-03-19	Novo Nordisk A/S	Insulin compositions and method of making a composition
JP5202338B2 (ja)	2006-02-27	2013-06-05	ノボ・ノルデイスク・エー／エス	新規インシュリン誘導体
US20090054305A1 (en)	2006-03-15	2009-02-26	Novo Nordisk A/S	Mixtures of Amylin and Insulin
US8796205B2 (en)	2006-05-09	2014-08-05	Novo Nordisk A/S	Insulin derivative
BRPI0712041A2 (pt)	2006-05-09	2011-12-27	Novo Nordisk As	derivado de insulina
HUE029512T2 (en)	2006-09-22	2017-03-28	Novo Nordisk As	Protease Resistant Insulin Analogs
JP5496082B2 (ja)	2007-04-30	2014-05-21	ノボ・ノルデイスク・エー／エス	タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
US20100190706A1 (en)	2007-06-01	2010-07-29	Novo Nordisk A/S	Stable Non-Aqueous Pharmaceutical Compositions
US20110144010A1 (en)	2007-06-01	2011-06-16	Novo Nordisk A/S	Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier
JP5552046B2 (ja)	2007-06-13	2014-07-16	ノボ・ノルデイスク・エー／エス	インスリン誘導体を含有する薬学的製剤
AU2009203809B2 (en)	2008-01-09	2013-07-25	Sanofi-Aventis Deutschland Gmbh	Novel insulin derivatives having an extremely delayed time-action profile
DE102008053048A1 (de)	2008-10-24	2010-04-29	Sanofi-Aventis Deutschland Gmbh	Kombination von einem Insulin und einem GLP-1-Agonisten
PT3228320T (pt)	2008-10-17	2020-03-26	Sanofi Aventis Deutschland	Combinação de uma insulina e de um agonista do glp-1
DE102008051834A1 (de)	2008-10-17	2010-04-22	Sanofi-Aventis Deutschland Gmbh	Kombination von einem Insulin und einem GLP-1-Agonisten
DE102009038210A1 (de)	2009-08-20	2011-03-03	Sanofi-Aventis Deutschland Gmbh	Kombination von einem Insulin und einem GLP-1-Agonisten
KR20110085985A (ko)	2008-10-30	2011-07-27	노보 노르디스크 에이/에스	하루 한번 주사 빈도보다 적은 인슐린 주사를 사용한 진성 당뇨병의 치료
KR101853606B1 (ko)	2009-07-06	2018-05-03	사노피-아벤티스 도이칠란트 게엠베하	메티오닌을 함유하는 수성 인슐린 제제
TW201105346A (en)	2009-07-06	2011-02-16	Sanofi Aventis Deutschland	Heat-stable and vibration-stable insulin preparations
JP5675799B2 (ja)	2009-07-06	2015-02-25	サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	遅効性インスリン製剤
SG178193A1 (en)	2009-07-31	2012-03-29	Sanofi Aventis Deutschland	Prodrugs comprising an insulin linker conjugate
SG178195A1 (en)	2009-07-31	2012-03-29	Sanofi Aventis Deutschland	Long acting insulin composition
KR101337322B1 (ko)	2009-11-13	2013-12-06	사노피-아벤티스 도이칠란트 게엠베하	Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
DK2498802T3 (en)	2009-11-13	2015-04-13	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
JP6249773B2 (ja)	2010-05-10	2017-12-20	ノヴォノルディスクアー／エス	インスリン−亜鉛錯体の調製方法
ES2606554T3 (es)	2010-08-30	2017-03-24	Sanofi-Aventis Deutschland Gmbh	Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
EP2438930A1 (en)	2010-09-17	2012-04-11	Sanofi-Aventis Deutschland GmbH	Prodrugs comprising an exendin linker conjugate
BR112013010345A2 (pt)	2010-10-27	2017-07-25	Novo Nordisk As	tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
US20130261051A1 (en)	2010-10-27	2013-10-03	Thue Johansen	Treating Diabetes Melitus Using Insulin Injections Administered With Varying Injection Intervals
CN102199206B (zh) *	2011-03-17	2013-03-20	甘李药业股份有限公司	快速起效且在酸性条件下稳定的胰岛素类似物及其制剂
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
PL2750699T3 (pl)	2011-08-29	2015-12-31	Sanofi Aventis Deutschland	Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2
AR087744A1 (es)	2011-09-01	2014-04-16	Sanofi Aventis Deutschland	Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
EP2844274B1 (en)	2012-05-01	2019-03-20	Novo Nordisk A/S	Pharmaceutical composition
WO2013173923A1 (en)	2012-05-25	2013-11-28	Diamedica, Inc.	Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
PT2854841T (pt)	2012-06-04	2017-05-15	Diamedica Inc	Isoformas de glicosilação da calicreína 1 em tecido humano
WO2014093696A2 (en)	2012-12-12	2014-06-19	Massachusetts Institute Of Technology	Insulin derivatives for diabetes treatment
MX360420B (es)	2012-12-19	2018-10-31	Wockhardt Ltd	Una composicion acuosa estable que comprende insulina humana o un analogo o derivado de la misma.
BR112015013223A2 (pt)	2012-12-26	2017-07-11	Wockhardt Ltd	composição farmacêutica
TWI641381B (zh)	2013-02-04	2018-11-21	法商賽諾菲公司	胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
AR095986A1 (es) *	2013-04-03	2015-11-25	Sanofi Sa	Proteínas modificadas que regulan glucosa en sangre con perfil alterado de actividad farmacológica y preparación de las mismas
JP2016519127A (ja)	2013-04-30	2016-06-30	ノヴォノルディスクアー／エス	新規投与レジメン
AU2014326181A1 (en)	2013-09-30	2016-03-17	Wockhardt Limited	Pharmaceutical composition
EP3091965A1 (en)	2014-01-09	2016-11-16	Sanofi	Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
CN112957455A (zh)	2014-01-09	2021-06-15	赛诺菲	胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
SG11201604706TA (en)	2014-01-09	2016-07-28	Sanofi Sa	Stabilized pharmaceutical formulations of insulin aspart
EP3154568A4 (en) *	2014-06-10	2018-01-24	California Institute of Technology	Non-canonical insulins and their uses
WO2016001862A1 (en)	2014-07-04	2016-01-07	Wockhardt Limited	Extended release formulations of insulins
AU2015359376B2 (en)	2014-12-12	2021-09-09	Sanofi-Aventis Deutschland Gmbh	Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
GB201607918D0 (en)	2016-05-06	2016-06-22	Arecor Ltd	Novel formulations
BR112019005637A2 (pt) *	2016-09-23	2019-07-30	Hanmi Pharm Ind Co Ltd	análogos da insulina com afinidade reduzida para o receptor de insulina e seu uso
EP3518893A1 (en)	2016-09-29	2019-08-07	Arecor Limited	Novel formulations
US11857608B2 (en)	2017-03-09	2024-01-02	Diamedica Inc.	Dosage forms of tissue kallikrein 1
GB201707189D0 (en)	2017-05-05	2017-06-21	Arecor Ltd	Novel formulations
GB201707188D0 (en)	2017-05-05	2017-06-21	Arecor Ltd	Novel formulations
GB201707187D0 (en)	2017-05-05	2017-06-21	Arecor Ltd	Novel formulations
CA3094237A1 (en)	2018-04-04	2019-10-10	Arecor Limited	Medical infusion pump system for the delivery of an insulin compound
WO2019193351A1 (en)	2018-04-04	2019-10-10	Arecor Limited	Medical infusion pump system for the delivery of an insulin compound
IL277731B2 (en)	2018-04-04	2024-03-01	Arecor Ltd	Medical infusion pump system for the delivery of an insulin compound
US10335464B1 (en)	2018-06-26	2019-07-02	Novo Nordisk A/S	Device for titrating basal insulin
KR20200082618A (ko)	2018-12-31	2020-07-08	주식회사 폴루스	인슐린 과발현용 램프 태그 및 이를 이용한 인슐린의 제조방법
US12343383B2 (en)	2019-07-12	2025-07-01	Novo Nordisk A/S	High concentration insulin formulation
CN118420744A (zh)	2019-12-30	2024-08-02	甘李药业股份有限公司	胰岛素衍生物
AU2020418207A1 (en)	2019-12-30	2022-08-25	Gan & Lee Pharmaceuticals Co., Ltd.	Long-acting GLP-1 compound
GB202004814D0 (en)	2020-04-01	2020-05-13	Arecor Ltd	Novel formulations
US20250340610A1 (en)	2022-01-28	2025-11-06	Gan & Lee Pharmaceuticals Co., Ltd.	Acylated insulin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3101382A1 (de) *	1981-01-17	1982-09-02	Hoechst Ag, 6000 Frankfurt	"verfahren zur herstellung von humanisulin oder dessen derivaten aus schweineinsulin oder dessen derivaten"
DK129385A (da) *	1985-03-22	1986-09-23	Novo Industri As	Peptider og fremstilling deraf
US5126249A (en) *	1989-05-09	1992-06-30	Eli Lilly And Company	Enzymatic removal of a protein amino-terminal sequence

1990
- 1990-02-05 PT PT93057A patent/PT93057B/pt active IP Right Grant
- 1990-02-05 IL IL9328290A patent/IL93282A/en not_active IP Right Cessation
- 1990-02-05 NZ NZ232375A patent/NZ232375A/en unknown
- 1990-02-06 CY CY191190A patent/CY1911A/xx unknown
- 1990-02-06 LU LU88831C patent/LU88831I2/fr unknown
- 1990-02-06 DE DE1990625210 patent/DE19675034I2/de active Active
- 1990-02-06 AT AT90301224T patent/ATE133961T1/de active
- 1990-02-06 DE DE69033889T patent/DE69033889T2/de not_active Expired - Lifetime
- 1990-02-06 EP EP90301224A patent/EP0383472B1/en not_active Expired - Lifetime
- 1990-02-06 EP EP95200804A patent/EP0678522B1/en not_active Expired - Lifetime
- 1990-02-06 DK DK95200804T patent/DK0678522T3/da active
- 1990-02-06 ES ES90301224T patent/ES2083424T3/es not_active Expired - Lifetime
- 1990-02-06 DE DE69025210T patent/DE69025210T2/de not_active Expired - Lifetime
- 1990-02-06 ES ES95200804T patent/ES2170122T3/es not_active Expired - Lifetime
- 1990-02-06 LU LU88830C patent/LU88830I2/fr unknown
- 1990-02-06 DK DK90301224.3T patent/DK0383472T3/da active
- 1990-02-07 IE IE44090A patent/IE73251B1/en not_active IP Right Cessation
- 1990-02-07 AU AU49226/90A patent/AU630912B2/en not_active Expired
- 1990-02-07 FI FI900600A patent/FI95915C/fi active IP Right Grant
- 1990-02-08 JP JP2031347A patent/JPH0822878B2/ja not_active Expired - Lifetime
- 1990-02-08 HU HU90726A patent/HU212679B/hu unknown
- 1990-02-08 NO NO900615A patent/NO179587C/no not_active IP Right Cessation
- 1990-02-08 CN CN90101415A patent/CN1034080C/zh not_active Expired - Lifetime
- 1990-02-08 KR KR1019900001498A patent/KR0169727B1/ko not_active Expired - Lifetime
- 1990-02-08 CA CA002009579A patent/CA2009579C/en not_active Expired - Lifetime
1991
- 1991-11-21 RU SU5010208A patent/RU2109749C1/ru active
1994
- 1994-02-25 BG BG098572A patent/BG60769B2/bg unknown
1995
- 1995-06-07 HU HU95P/P00171P patent/HU211276A9/hu unknown
1996
- 1996-04-02 GR GR960400889T patent/GR3019501T3/el unknown
- 1996-04-03 HK HK60296A patent/HK60296A/en not_active IP Right Cessation
- 1996-05-23 CN CN96106635A patent/CN1103602C/zh not_active Ceased
- 1996-10-17 NL NL960026C patent/NL960026I2/nl unknown
- 1996-12-09 NO NO1996013C patent/NO1996013I1/no unknown

Also Published As

Publication number	Publication date
EP0383472A3 (en)	1991-09-18
CA2009579A1 (en)	1990-08-09
NO179587C (no)	1996-11-06
ES2170122T3 (es)	2002-08-01
ES2083424T3 (es)	1996-04-16
DK0678522T3 (da)	2002-03-11
NO900615L (no)	1990-08-10
DE69033889T2 (de)	2002-08-22
HU212679B (en)	1996-09-30
IE73251B1 (en)	1997-05-21
CY1911A (en)	1990-02-06
JPH02264798A (ja)	1990-10-29
FI95915C (fi)	1996-04-10
HUT57795A (en)	1991-12-30
ATE133961T1 (de)	1996-02-15
HK60296A (en)	1996-04-12
EP0678522B1 (en)	2002-01-02
CN1034080C (zh)	1997-02-19
NL960026I2 (nl)	1997-05-01
DE69025210T2 (de)	1996-06-13
HU900726D0 (en)	1990-04-28
JPH0822878B2 (ja)	1996-03-06
IE900440L (en)	1990-08-09
CA2009579C (en)	2000-04-11
CN1103602C (zh)	2003-03-26
CN1148984A (zh)	1997-05-07
NZ232375A (en)	1992-04-28
KR900012627A (ko)	1990-09-01
EP0678522A1 (en)	1995-10-25
AU4922690A (en)	1990-08-16
DK0383472T3 (da)	1996-05-06
NO179587B (no)	1996-07-29
AU630912B2 (en)	1992-11-12
HU211276A9 (en)	1995-11-28
BG60769B2 (bg)	1996-02-29
FI900600A0 (fi)	1990-02-07
DE69033889D1 (de)	2002-02-07
NL960026I1 (nl)	1997-01-06
DE19675034I2 (de)	2006-11-16
IL93282A (en)	1995-08-31
EP0383472A2 (en)	1990-08-22
KR0169727B1 (ko)	1999-01-15
RU2109749C1 (ru)	1998-04-27
DE69025210D1 (de)	1996-03-21
PT93057B (pt)	1995-12-29
CN1044820A (zh)	1990-08-22
FI95915B (fi)	1995-12-29
NO1996013I1 (no)	1996-12-09
LU88830I2 (fr)	1997-01-06
LU88831I2 (fr)	1997-01-10
NO900615D0 (no)	1990-02-08
EP0383472B1 (en)	1996-02-07
IL93282A0 (en)	1990-11-29
GR3019501T3 (en)	1996-07-31

Legal Events

Date	Code	Title	Description
1995-12-29	FG3A	Patent granted, date of granting	Effective date: 19950929

Publication	Publication Date	Title
ES2083424T3 (es)	1996-04-16	Analogos de insulina.
HU906177D0 (en)	1991-08-28	Process for the production of peptide derivatives and medical and diagnostical preparations containing such derivatives
PE47096A1 (es)	1996-11-12	Analogo, composicion y uso del peptido insulinotropico similar al glucagon
WO2000012542A3 (en)	2000-06-29	Cytotoxic lactoferrin derivatives modified by bulky or lipophilic moieties
NZ517012A (en)	2003-02-28	Peptides that lower blood glucose levels
CA2073856A1 (en)	1991-07-25	Glp-1 analogs useful for diabetes treatment
ATE95195T1 (de)	1993-10-15	Mikroproteine, verfahren zur herstellung derselben und anwendung dieser mikroproteine als arzneimittel.
FI925972A0 (fi)	1992-12-31	Ny polypeptid med affinitet till lipopolysackarider och dess anvaendning
KR910002899A (ko)	1991-02-26	혈조절 펩타이드
DE69302921D1 (de)	1996-07-11	Neue Peptidderivate, Verfahren zu deren Herstellung und deren Anwendung als Heilmittel
KR920012114A (ko)	1992-07-25	사람 면역결핍 바이러스(HIV)의 그룹-특이 항원(gaa)의 선택된 펩타이드, 이의 제법 및 용도
ES2135389T3 (es)	1999-11-01	Antagonistas de endotelina.
DK0491361T3 (da)	1999-10-11	Korte peptider med insulinvirkning
ATE207496T1 (de)	2001-11-15	Neue peptide und nootroper wirkstoff
RU93004930A (ru)	1996-01-27	Днк, соматотропин, плазмиды, рекомбинантные организмы, композиция, способ получения соматотропина, способы стимулирования роста